Actinium Pharmaceuticals Inc. (ATNM) 3.60 $ATNM
Principal Investigator Dr. John Pagel to Brief Clinicians From Major Bone Marrow Transplant Centers on Upcoming Pivotal Trial of Iomab-B
Marketwired - Thu Feb 12, 6:03AM CST
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"
, a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that John Pagel, MD, PhD, Chairman of Actinium's Scientific Advisory Board and head of the Swedish Cancer Institute Hematologic Malignancies Program in Seattle, along with Dragan Cicic, MD, the Company's Chief Medical Officer, will discuss the potential of Iomab-B and its upcoming Phase 3 clinical trial with key bone marrow transplanters from major medical centers throughout the US. This drug candidate may address significant unmet medical need in older acute myeloid leukemia (AML) patients.
ATNM: 3.60 (-0.29)
CapRock Research Initiates Analyst Coverage of Actinium Pharmaceuticals: Targeting a Killer Issued by Small Cap IR
PR Newswire - Thu Feb 12, 6:00AM CST
Analyst report issued by Small Cap IR. According to the World Health Organization, over 14 million new cases of cancer are reported each year, and cancer cases are expected to surge 57% worldwide over the next 20 years. The fastest growing hospital treatment in the United States to treat this disease is Hematopoietic Stem Cell Transplantation; the transplantation of multipotent hematopoietic stem cells derived from bone marrow, peripheral blood, or umbilical cord blood.
ATNM: 3.60 (-0.29)
Actinium Announces Closing of Public Offering of Common Stock and Warrants
Marketwired - Wed Feb 11, 4:38PM CST
Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company" (NYSE MKT: ATNM), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the closing of its previously announced underwritten public offering of an aggregate of 4,444,444 shares of the Company's common stock and warrants to purchase an aggregate of 3,333,333 shares of common stock at a combined price to the public of $4.50. The shares of common stock and warrants were issued separately. The warrants will be exercisable for a period of 4 years following the issuance thereof at an exercise price of $6.50 per share. There is no established public trading market for the warrants and Actinium does not expect a market to develop in the future. In addition, Actinium has granted the underwriters a 30-day option to purchase up to an additional 666,666 shares of common stock and warrants to purchase 499,999 shares of common stock solely to cover over-allotments, if any.
ATNM: 3.60 (-0.29)
Actinium's Chief Medical Officer to Participate in the Next Gen Immunotherapeutics Panel at the 3rd Annual Sachs Cancer Bio Partnering & Investment Forum on February 23rd
Marketwired - Mon Feb 09, 6:00AM CST
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company" , a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that Dr. Dragan Cicic, Chief Medical Officer of Actinium will participate in the Next Gen Immunotherapeutics panel discussion on Monday, February 23, 2015 at 9:45 a.m. as part of the 3rd Annual Sachs Cancer Bio Partnering and Investment Forum in New York, NY.
ATNM: 3.60 (-0.29)
Actinium Pharma prices offering
Seeking Alpha - at Seeking Alpha - Fri Feb 06, 7:37AM CST
ATNM: 3.60 (-0.29)
Actinium Announces Pricing of Public Offering of Common Stock and Warrants to Purchase Common Stock
Business Wire - Fri Feb 06, 7:22AM CST
Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company" (NYSE MKT:ATNM), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the pricing of an underwritten public offering of an aggregate 4,444,444 shares of its common stock and warrants to purchase an aggregate of 3,333,333 shares of the Company's common stock at a combined price to the public of $4.50. The shares of common stock and warrants will be issued separately. The warrants will be exercisable for a period of 4 years following the issuance thereof at an exercise price of $6.50 per share. The warrants will be certificated, and will be delivered to the investors by physical delivery at the closing. There is no established public trading market for the warrants and Actinium does not expect a market to develop in the future. In addition, Actinium has granted the underwriters a 30-day option to purchase up to an additional 666,666 shares of common stock and warrants to purchase 499,999 shares of common stock solely to cover over-allotments, if any. The offering is expected to close on or about February 11, 2015, subject to customary closing conditions.
ATNM: 3.60 (-0.29)
Actinium Pharma to execute public offering
Seeking Alpha - at Seeking Alpha - Fri Feb 06, 6:15AM CST
ATNM: 3.60 (-0.29)
Actinium Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock
Marketwired - Thu Feb 05, 4:03PM CST
Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company" (NYSE MKT: ATNM), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that it intends to offer shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 15 percent (15%) of the number of shares of common stock and warrants sold in the offering solely to cover over-allotments, if any. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
ATNM: 3.60 (-0.29)
Actinium Engages Dr. Roland Turck, Former President, Global Specialty Medicine, Bayer Healthcare as Board Advisor
Marketwired - Wed Feb 04, 6:19AM CST
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company" , a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that it engaged Dr. Roland Turck, Managing Partner at TurckBio, as a senior advisor to the Board of Directors. Prior to founding TurckBio, Dr. Turck led Bayer Healthcare's Global Specialty Medicine unit, where most relevant to Actinium, he played a leadership role in the commercialization of the alpha-radiopharmaceutical Xofigo® whose successful launch he prepared in close collaboration with Algeta ASA.
ATNM: 3.60 (-0.29)
Actinium to Present at the 17th Annual BIO CEO & Investor Conference
Marketwired - Tue Feb 03, 6:02AM CST
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company" , a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that a corporate overview will be presented at the 17th Annual BIO CEO & Investor Conference. Hosted by the Biotechnology Industry Organization (BIO), the 17th Annual BIO CEO & Investor Conference will take place February 9-10 at the Waldorf Astoria in New York City.
ATNM: 3.60 (-0.29)
Actinium to Participate in the Canaccord Genuity Rare Disease and Biopharma One-on-One Day on February 3rd
Marketwired - Wed Jan 28, 6:02AM CST
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company" , a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that Mr. Sandesh Seth, Executive Chairman of Actinium, and other members of the management team will be attending the Canaccord Genuity Rare Disease and Biopharma One-on-One Day on Tuesday, February 3, 2015.
ATNM: 3.60 (-0.29)
Actinium jumps on Iomab-B progress
Seeking Alpha - at Seeking Alpha - Mon Jan 26, 3:02PM CST
ATNM: 3.60 (-0.29)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jan 26, 11:46AM CST
HTBX: 5.83 (+0.22), NES: 3.52 (+0.13), TEAR: 2.15 (+0.03), FENG: 7.92 (+0.23), OCN: 9.10 (+0.09), STX: 61.83 (+0.67), LACO: 8.38 (+0.17), PHMD: 1.68 (+0.04), BBEP: 7.85 (+0.32), HGSH: 3.05 (-0.13), MBT: 10.36 (+0.62), NBG: 1.61 (+0.18), NDRM: 10.76 (+0.22), PT: 0.83 (+0.04), POST: 48.62 (-0.25), ATNM: 3.60 (-0.29), MWV: 53.91 (+0.59), WRES: 1.27 (+0.01), IDN: 1.43 (-0.01), KONE: 4.20 (+0.03)
Actinium Submits Pre-IND Meeting Request to the U.S. FDA for its Iomab-B Drug Candidate
Marketwired - Mon Jan 26, 6:02AM CST
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company" , a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that it has submitted a request for a pre-IND (Investigational New Drug) meeting to the U.S. Food and Drug Administration (FDA) for the company's Iomab-B drug candidate currently undergoing final preparations to start the pivotal Phase 3 trial in mid-2015. The goal of the pre-IND meeting is to finalize preparations for the final stages of its Iomab-B drug candidate development. The initial indication for Iomab-B is conditioning for bone marrow transplant in older relapsed and refractory acute myeloid leukemia (AML) patients, for which there are no FDA approved therapies.
ATNM: 3.60 (-0.29)
Principal Investigator Dr. John Pagel to Brief Clinicians From Major Bone Marrow Transplant Centers on Upcoming Pivotal Trial of Iomab-B
Marketwired - Thu Feb 12, 6:03AM CST
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"
, a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that John Pagel, MD, PhD, Chairman of Actinium's Scientific Advisory Board and head of the Swedish Cancer Institute Hematologic Malignancies Program in Seattle, along with Dragan Cicic, MD, the Company's Chief Medical Officer, will discuss the potential of Iomab-B and its upcoming Phase 3 clinical trial with key bone marrow transplanters from major medical centers throughout the US. This drug candidate may address significant unmet medical need in older acute myeloid leukemia (AML) patients. ATNM: 3.60 (-0.29)
CapRock Research Initiates Analyst Coverage of Actinium Pharmaceuticals: Targeting a Killer Issued by Small Cap IR
PR Newswire - Thu Feb 12, 6:00AM CST
Analyst report issued by Small Cap IR. According to the World Health Organization, over 14 million new cases of cancer are reported each year, and cancer cases are expected to surge 57% worldwide over the next 20 years. The fastest growing hospital treatment in the United States to treat this disease is Hematopoietic Stem Cell Transplantation; the transplantation of multipotent hematopoietic stem cells derived from bone marrow, peripheral blood, or umbilical cord blood.
ATNM: 3.60 (-0.29)
Actinium Announces Closing of Public Offering of Common Stock and Warrants
Marketwired - Wed Feb 11, 4:38PM CST
Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company"
(NYSE MKT: ATNM), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the closing of its previously announced underwritten public offering of an aggregate of 4,444,444 shares of the Company's common stock and warrants to purchase an aggregate of 3,333,333 shares of common stock at a combined price to the public of $4.50. The shares of common stock and warrants were issued separately. The warrants will be exercisable for a period of 4 years following the issuance thereof at an exercise price of $6.50 per share. There is no established public trading market for the warrants and Actinium does not expect a market to develop in the future. In addition, Actinium has granted the underwriters a 30-day option to purchase up to an additional 666,666 shares of common stock and warrants to purchase 499,999 shares of common stock solely to cover over-allotments, if any. ATNM: 3.60 (-0.29)
Actinium's Chief Medical Officer to Participate in the Next Gen Immunotherapeutics Panel at the 3rd Annual Sachs Cancer Bio Partnering & Investment Forum on February 23rd
Marketwired - Mon Feb 09, 6:00AM CST
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"
, a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that Dr. Dragan Cicic, Chief Medical Officer of Actinium will participate in the Next Gen Immunotherapeutics panel discussion on Monday, February 23, 2015 at 9:45 a.m. as part of the 3rd Annual Sachs Cancer Bio Partnering and Investment Forum in New York, NY. ATNM: 3.60 (-0.29)
Actinium Pharma prices offering
Seeking Alpha - at Seeking Alpha - Fri Feb 06, 7:37AM CST
ATNM: 3.60 (-0.29)
Actinium Announces Pricing of Public Offering of Common Stock and Warrants to Purchase Common Stock
Business Wire - Fri Feb 06, 7:22AM CST
Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company"
(NYSE MKT:ATNM), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the pricing of an underwritten public offering of an aggregate 4,444,444 shares of its common stock and warrants to purchase an aggregate of 3,333,333 shares of the Company's common stock at a combined price to the public of $4.50. The shares of common stock and warrants will be issued separately. The warrants will be exercisable for a period of 4 years following the issuance thereof at an exercise price of $6.50 per share. The warrants will be certificated, and will be delivered to the investors by physical delivery at the closing. There is no established public trading market for the warrants and Actinium does not expect a market to develop in the future. In addition, Actinium has granted the underwriters a 30-day option to purchase up to an additional 666,666 shares of common stock and warrants to purchase 499,999 shares of common stock solely to cover over-allotments, if any. The offering is expected to close on or about February 11, 2015, subject to customary closing conditions. ATNM: 3.60 (-0.29)
Actinium Pharma to execute public offering
Seeking Alpha - at Seeking Alpha - Fri Feb 06, 6:15AM CST
ATNM: 3.60 (-0.29)
Actinium Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock
Marketwired - Thu Feb 05, 4:03PM CST
Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company"
(NYSE MKT: ATNM), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that it intends to offer shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 15 percent (15%) of the number of shares of common stock and warrants sold in the offering solely to cover over-allotments, if any. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. ATNM: 3.60 (-0.29)
Actinium Engages Dr. Roland Turck, Former President, Global Specialty Medicine, Bayer Healthcare as Board Advisor
Marketwired - Wed Feb 04, 6:19AM CST
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"
, a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that it engaged Dr. Roland Turck, Managing Partner at TurckBio, as a senior advisor to the Board of Directors. Prior to founding TurckBio, Dr. Turck led Bayer Healthcare's Global Specialty Medicine unit, where most relevant to Actinium, he played a leadership role in the commercialization of the alpha-radiopharmaceutical Xofigo® whose successful launch he prepared in close collaboration with Algeta ASA. ATNM: 3.60 (-0.29)
Actinium to Present at the 17th Annual BIO CEO & Investor Conference
Marketwired - Tue Feb 03, 6:02AM CST
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"
, a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that a corporate overview will be presented at the 17th Annual BIO CEO & Investor Conference. Hosted by the Biotechnology Industry Organization (BIO), the 17th Annual BIO CEO & Investor Conference will take place February 9-10 at the Waldorf Astoria in New York City. ATNM: 3.60 (-0.29)
Actinium to Participate in the Canaccord Genuity Rare Disease and Biopharma One-on-One Day on February 3rd
Marketwired - Wed Jan 28, 6:02AM CST
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"
, a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that Mr. Sandesh Seth, Executive Chairman of Actinium, and other members of the management team will be attending the Canaccord Genuity Rare Disease and Biopharma One-on-One Day on Tuesday, February 3, 2015. ATNM: 3.60 (-0.29)
Actinium jumps on Iomab-B progress
Seeking Alpha - at Seeking Alpha - Mon Jan 26, 3:02PM CST
ATNM: 3.60 (-0.29)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jan 26, 11:46AM CST
HTBX: 5.83 (+0.22), NES: 3.52 (+0.13), TEAR: 2.15 (+0.03), FENG: 7.92 (+0.23), OCN: 9.10 (+0.09), STX: 61.83 (+0.67), LACO: 8.38 (+0.17), PHMD: 1.68 (+0.04), BBEP: 7.85 (+0.32), HGSH: 3.05 (-0.13), MBT: 10.36 (+0.62), NBG: 1.61 (+0.18), NDRM: 10.76 (+0.22), PT: 0.83 (+0.04), POST: 48.62 (-0.25), ATNM: 3.60 (-0.29), MWV: 53.91 (+0.59), WRES: 1.27 (+0.01), IDN: 1.43 (-0.01), KONE: 4.20 (+0.03)
Actinium Submits Pre-IND Meeting Request to the U.S. FDA for its Iomab-B Drug Candidate
Marketwired - Mon Jan 26, 6:02AM CST
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"
, a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that it has submitted a request for a pre-IND (Investigational New Drug) meeting to the U.S. Food and Drug Administration (FDA) for the company's Iomab-B drug candidate currently undergoing final preparations to start the pivotal Phase 3 trial in mid-2015. The goal of the pre-IND meeting is to finalize preparations for the final stages of its Iomab-B drug candidate development. The initial indication for Iomab-B is conditioning for bone marrow transplant in older relapsed and refractory acute myeloid leukemia (AML) patients, for which there are no FDA approved therapies. ATNM: 3.60 (-0.29)
